Aiming at clinical characteristics, we found there was a significant differential FDX1 expression in WHO Grade II, WHO Grade III, and WHO Grade IV (p = 0.001), and FDX1 was highly expressed in WHO IV (GBM) compared with WHO II, III (LGG) (Figure 7A), consistent with the result in TCGA-GBM and TCGA-LGG (Figures 1A, B). Here, FDX1 is linked to glioblastoma.